세계의 전두측두엽 치매 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 약제 클래스별, 적응 질환별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Frontotemporal Dementia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Disease Indication, By Distribution Channel, By Region & Competition, 2020-2030F
상품코드:1778939
리서치사:TechSci Research
발행일:2025년 07월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 전두측두엽 치매 시장 규모는 2024년 2억 4,136만 달러였고, 예측 기간 중 CAGR 6.39%로 견조한 성장이 예측되고 있습니다.
전두측두엽 질환은 뇌의 전두엽 또는 측두엽의 신경세포의 변성을 특징으로 하는 신경질환입니다. 전두측두엽 변성증으로도 알려진 전두측두엽 장애는 주로 전두엽과 측두엽에 영향을 미치는 뇌장해의 일종입니다. 이 질환은 신경세포의 진행성 상실과 치매의 개발을 특징으로 합니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
2억 4,136만 달러
시장 규모 : 2030년
3억 4,718만 달러
CAGR : 2025-2030년
6.39%
급성장 부문
인지기능 향상약
최대 시장
북미
예를 들어, 핀란드에서 실시된 2025년 연구에서는 245명의 전두측두엽 치매(FTD) 환자, 1,300명 이상의 알츠하이머병(AD) 환자, 2,400명 이상의 연령, 성별, 장소를 매치시킨 건강 대조자에서의 간질의 유병률과 항간질제의 사용이 비교되었습니다. FTD 환자의 평균 진단연령은 65세(여성 49%), AD 환자의 평균 진단 연령은 72세(여성 59%)였습니다.
주요 시장 성장 촉진요인
FTD 치료 개발 증가 및 자금 증가
주요 시장 과제
신경 질환의 오진
주요 시장 동향
의약품 승인 증가 및 치료 고도화
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 임상 검사 분석
제6장 세계의 전두측두엽 치매 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
약제 클래스별(인지기능 향상약, 항정신병제, 항우울제, 중추신경자극제, 기타 약제 클래스)
적응 질환별(전두측두엽 치매, 원발성 진행성 실어증, 운동 장애)
유통 채널별(병원 약국, 소매 약국, 온라인 약국)
지역별
기업별(2024년)
시장 맵
제7장 북미의 전두측두엽 치매 시장 전망
시장 규모와 예측
시장 점유율 및 예측
북미: 국가별 분석
미국
캐나다
멕시코
제8장 유럽의 전두측두엽 치매 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽: 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제9장 아시아태평양 전두측두엽 치매 시장 전망
시장 규모와 예측
시장 점유율 및 예측
아시아태평양: 국가별 분석
중국
인도
일본
한국
호주
제10장 남미의 전두측두엽 치매 시장 전망
시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제11장 중동 및 아프리카의 전두측두엽 치매 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카: 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제12장 시장 역학
성장 촉진요인
과제
제13장 시장 동향과 발전
합병과 인수
제품 출시
제14장 세계의 전두측두엽 치매 시장 : SWOT 분석
제15장 Porter's Five Forces 분석
산업 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제16장 경쟁 구도
Transposon Therapeutics
Alector Inc.
Denali Therapeutics Inc.
Pfizer Inc.
Johnson & Johnson Services Inc.
Prevail Therapeutics
Wave Life Sciences
AstraZeneca plc
GlaxoSmithKline plc
TauRx Pharmaceuticals Ltd.
제17장 전략적 제안
제18장 기업 소개와 면책사항
JHS
영문 목차
영문목차
Global Frontotemporal Dementia Market was valued at USD 241.36 Million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.39% through 2030F. Frontotemporal diseases are a neurological condition characterized by the degeneration of nerve cells in the frontal or temporal lobes of the brain. This condition, which includes dementia, progressive supranuclear palsy, and primary progressive aphasia, significantly impacts behavior, language, movement, and personality, thereby impairing individuals' ability to perform daily activities. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are a type of brain disorder that primarily affects the frontal and temporal lobes. This condition is characterized by the progressive loss of nerve cells and the development of dementia.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 241.36 Million
Market Size 2030
USD 347.18 Million
CAGR 2025-2030
6.39%
Fastest Growing Segment
Cognitive Enhancers
Largest Market
North America
For instance, a 2025 study from Finland compared epilepsy prevalence and antiseizure medication use among 245 frontotemporal dementia (FTD) patients, over 1,300 Alzheimer's disease (AD) patients, and more than 2,400 age-, sex-, and location-matched healthy controls. FTD patients had a mean diagnosis age of 65 (49% women), while AD patients averaged 72 years (59% women). The typical age range for the onset of frontotemporal disorder is between 40 and 60 years, although it can occur after the age of 60. Following diagnosis, the average life expectancy is approximately 8-10 years. Given its significant impact on the healthcare sector, it is projected that frontotemporal disorders will experience substantial growth in the forecast period.
Key Market Drivers
Increasing FTD Drug Development and Increasing Funds
Non-profit organizations and disease advocacy groups, as well as private organizations, are currently focused on supporting the development of drugs for Frontotemporal Degeneration (FTD) due to the expanding patient population. Research funding initiatives from notable non-profit organizations, such as the Association for Frontotemporal Degeneration (AFTD), Bluefield Project Organization, Tau Consortium Organization, Alzheimer Discovery Foundation (ADDF), and CurePSP, Inc., have played a significant role in stimulating research efforts for the treatment of frontotemporal disorders. These organizations provide support for both clinical and preclinical trials aimed at testing novel therapeutics that can intervene to slow down or halt the progression of FTD and other rare neurological diseases. This, in turn, contributes to the growth of the market. For instance, a 2025 study revealed that epileptic seizures are significantly more common in patients with frontotemporal dementia (FTD) than previously believed. This finding enhances understanding of FTD symptoms and highlights the need to consider seizures in patient care. Led by Neurocenter Finland, the University of Eastern Finland and University of Oulu conducted the research, published in JAMA Neurology, using one of the world's largest FTD datasets.
Grants and funding provide resources to support FTD-focused research initiatives. This includes investigations into the underlying mechanisms of the disease, identification of potential drug targets, and the development of novel therapeutic approaches. Drug development in FTD necessitates rigorous clinical trials to evaluate the safety and efficacy of potential treatments. Grants and funding support the design, implementation, and monitoring of these trials, facilitating the testing of new therapies. Adequate funding enhances the attractiveness of FTD research for scientists and researchers. This can lead to increased participation, collaboration, and expertise focused on FTD drug development efforts. Funding enables the exploration of innovative therapeutic strategies, including small molecules, biologics, gene therapies, and personalized medicine approaches tailored to the unique characteristics of FTD patients. Grants and funding assist in the identification and validation of promising drug targets for FTD. This step is crucial in developing treatments that address the underlying causes of the disease.
Key Market Challenges
Misdiagnosis of Neurological Disorders
Multiple frontotemporal disorders are frequently misdiagnosed as depression, Parkinson's disease, Alzheimer's disease, or other psychiatric conditions. This hinders the potential for implementing appropriate treatment for neurological conditions. Misdiagnosis often leads to delayed initiation of appropriate treatment for the underlying FTD. This can result in missed opportunities for interventions that could slow disease progression or manage symptoms effectively. Treating FTD patients based on misdiagnosed conditions can result in ineffective or even harmful treatments. Medications commonly used for depression or other psychiatric disorders may not address the specific cognitive, behavioral, and functional challenges of FTD. Without proper treatment, FTD symptoms can worsen over time, leading to greater impairment in daily functioning and quality of life. Misdiagnosis can lead to unnecessary medical expenses, as well as wasted time and resources on treatments that are unlikely to be effective. Accurate diagnosis is crucial for enrolling eligible patients in clinical trials for FTD-specific treatments. Misdiagnosis can exclude patients from potential participation and hinder the development of targeted therapies.
Key Market Trends
Higher Drug Approvals and Advanced Treatment
Several antidepressant drugs are utilized for the treatment of major depressive disorders and other conditions, such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, eating disorders, chronic pain, and neuropathic pain. For example, in October 2018, Lundbeck introduced Brintellix tablets for the treatment of Major Depressive Disorder in India. Similarly, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market, specifically for the treatment of major depressive disorder and obsessive-compulsive disorder. These initiatives contribute significantly to the growth of the market.
Drug approvals provide patients with access to treatments that can potentially slow down disease progression, manage symptoms, and improve quality of life. This leads to higher demand for treatments among FTD patients and healthcare providers. Effective treatments often come with improved diagnostic methods, biomarkers, and screening tools. This facilitates early diagnosis and patient identification, leading to an increased pool of eligible patients seeking treatment. Approved treatments can contribute to better patient outcomes, including improved cognitive function, reduced behavioral symptoms, and enhanced daily functioning. Positive outcomes drive higher demand for these treatments. Drug approvals garner media attention and raise awareness among patients, caregivers, and the general public. This increased awareness leads to more individuals seeking diagnosis and treatment options for FTD. Successful drug approvals indicate a growing interest in FTD research and development. This encourages pharmaceutical companies, researchers, and investors to invest more resources into finding innovative treatments.
Key Market Players
Transposon Therapeutics
Alector Inc.
Denali Therapeutics Inc.
Pfizer Inc.
Johnson & Johnson Services Inc.
Prevail Therapeutics
Wave Life Sciences
AstraZeneca plc
GlaxoSmithKline plc
TauRx Pharmaceuticals Ltd.
Report Scope:
In this report, the Global Frontotemporal Dementia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Frontotemporal Dementia Market, By Drug Class:
Cognitive Enhancers
Antipsychotics
Antidepressants
CNS Stimulants
Other Drug Classes
Frontotemporal Dementia Market, By Disease Indication:
Frontotemporal Dementia
Primary Progressive Aphasia
Movement Disorders
Frontotemporal Dementia Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Frontotemporal Dementia Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Frontotemporal Dementia Market.
Available Customizations:
Global Frontotemporal Dementia market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Frontotemporal Dementia Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, and Other Drug Classes)
6.2.2. By Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, and Movement Disorders)
6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
6.2.4. By Region
6.2.5. By Company (2024)
6.3. Market Map
7. North America Frontotemporal Dementia Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Disease Indication
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Frontotemporal Dementia Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Disease Indication
7.3.1.2.3. By Distribution Channel
7.3.2. Canada Frontotemporal Dementia Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Disease Indication
7.3.2.2.3. By Distribution Channel
7.3.3. Mexico Frontotemporal Dementia Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Disease Indication
7.3.3.2.3. By Distribution Channel
8. Europe Frontotemporal Dementia Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Disease Indication
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. Germany Frontotemporal Dementia Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Disease Indication
8.3.1.2.3. By Distribution Channel
8.3.2. United Kingdom Frontotemporal Dementia Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Disease Indication
8.3.2.2.3. By Distribution Channel
8.3.3. Italy Frontotemporal Dementia Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecasty
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Disease Indication
8.3.3.2.3. By Distribution Channel
8.3.4. France Frontotemporal Dementia Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Disease Indication
8.3.4.2.3. By Distribution Channel
8.3.5. Spain Frontotemporal Dementia Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Disease Indication
8.3.5.2.3. By Distribution Channel
9. Asia-Pacific Frontotemporal Dementia Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Disease Indication
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Frontotemporal Dementia Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Disease Indication
9.3.1.2.3. By Distribution Channel
9.3.2. India Frontotemporal Dementia Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Disease Indication
9.3.2.2.3. By Distribution Channel
9.3.3. Japan Frontotemporal Dementia Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Disease Indication
9.3.3.2.3. By Distribution Channel
9.3.4. South Korea Frontotemporal Dementia Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Class
9.3.4.2.2. By Disease Indication
9.3.4.2.3. By Distribution Channel
9.3.5. Australia Frontotemporal Dementia Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Drug Class
9.3.5.2.2. By Disease Indication
9.3.5.2.3. By Distribution Channel
10. South America Frontotemporal Dementia Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Disease Indication
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Frontotemporal Dementia Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Disease Indication
10.3.1.2.3. By Distribution Channel
10.3.2. Argentina Frontotemporal Dementia Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Disease Indication
10.3.2.2.3. By Distribution Channel
10.3.3. Colombia Frontotemporal Dementia Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Disease Indication
10.3.3.2.3. By Distribution Channel
11. Middle East and Africa Frontotemporal Dementia Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Class
11.2.2. By Disease Indication
11.2.3. By Distribution Channel
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Frontotemporal Dementia Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Disease Indication
11.3.1.2.3. By Distribution Channel
11.3.2. Saudi Arabia Frontotemporal Dementia Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Disease Indication
11.3.2.2.3. By Distribution Channel
11.3.3. UAE Frontotemporal Dementia Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Class
11.3.3.2.2. By Disease Indication
11.3.3.2.3. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Development
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Global Frontotemporal Dementia Market: SWOT Analysis
